ctp-499
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01328821)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ctp-499
- ctp-499
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04800562 | Phase 2 | Apr 12, 2021 | Processa Pharmaceuticals |
| NCT03698864 | Phase 2 | Nov 7, 2018 | Processa Pharmaceuticals |
| NCT03836222 | Phase 1 | Feb 26, 2018 | Processa Pharmaceuticals, Quotient |
| NCT01487109 | Phase 2 | Jan 1, 2012 | Concert Pharmaceuticals |
| NCT01460199 | Phase 1 | Aug 1, 2011 | Concert Pharmaceuticals |
| NCT01328821 | Phase 1 | Mar 1, 2011 | Concert Pharmaceuticals, Frontage Laboratories, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Concert Pharmaceuticals | For profit | 3 | 3 | 2 | 2011 |
| Processa Pharmaceuticals | For profit | 3 | 3 | 2 | 2018 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2011 |
| Quotient | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1